1 / 44

Final Exam

Final Exam. Tuesday, 6/5, 2 PM Closed book Essay and MC/TF Determining Energy Needs p234-246 Indirect calorimetry Be able to do the calculations given RQ table, VO2, VCO2 Principles of indirect calorimetry Don’t memorize H-B or WHO equations. Final Exam. Protein status

theresa
Download Presentation

Final Exam

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Final Exam • Tuesday, 6/5, 2 PM • Closed book • Essay and MC/TF • Determining Energy Needs • p234-246 • Indirect calorimetry • Be able to do the calculations given RQ table, VO2, VCO2 • Principles of indirect calorimetry • Don’t memorize H-B or WHO equations

  2. Final Exam • Protein status • AMA (will give you equations, 233-234) • Biochemical assessments (321-327) • Iron status (327-332) • Know markers (and their rationale) of iron status • Be able to interpret lab values • Glucose (fasting & GTT) (303-307) • principle & interpretation • Lipoproteins & CHD (262-272) • Assessment only, not treatment • CHD risk assessment using ATP III • Know cut points

  3. Update: Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) David L. Gee, PhD Professor of Food Science and Nutrition Central Washington University

  4. National Cholesterol Education Program (NCEP)History • Adult Treatment Panel I (ATP I) • 1988 • strategy for primary prevention of CHD • established cutoff values for TC, HDL-C, LDL-C and CHD risk factors

  5. National Cholesterol Education Program (NCEP) • Children’s Treatment Panel • 1991 • ATP II • 1993 • reaffirmed ATP I • secondary prevention of CHD

  6. National Cholesterol Education Program (NCEP) • ATP III • May 2001 • reaffirms ATP I, II • New features • primary prevention in persons with multiple risk factors • modifies lipid classifications • modifies implementation of prevention measures

  7. Initial CHD Risk Assessment • Fasting lipoprotein profile • adults > 20 yrs old • every 5 years • TC, LDL-C, HDL-C, TG • Non-fasted blood sample • only TC and HDL-C usable • LDL-C = TC - HDL-C - (TG/5)

  8. ATP III Classification of LDL- Cholesterol (mg/dl) • LDL Cholesterol • < 100 optimal • 100-129 near/above optimal • 130-159 borderline high • 160-189 high • >190 very high

  9. ATP III Classification of Total and HDL Cholesterol (mg/dl) • Total Cholesterol • <200 desirable • 200-239 borderline high • >240 high • HDL Cholesterol • <40 low (bad) • >60 high(good)

  10. Risk Category LDL Goal(mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (TLC) (mg/dL) LDL Level at Which to ConsiderDrug Therapy (mg/dL) CHD or CHD Risk Equivalents(10-year risk >20%) <100 100 130 (100–129: drug optional) 2+ Risk Factors (10-year risk 20%) <130 130 10-year risk 10–20%: 130 10-year risk <10%: 160 0–1 Risk Factor <160 160 190 (160–189: LDL-lowering drug optional) LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)and Drug Therapy in Different Risk Categories

  11. CHD Risk Equivalents • Have risk of major coronary event equal to that of established CHD • Other forms of atherosclerotic disease • peripheral arterial disease • abdominal aortic aneurysm • symptomatic carotid artery disease • Diabetes • Multiple risk factors that confer a 10-year risk for CHD > 20%

  12. Risk Category LDL Goal(mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (TLC) (mg/dL) LDL Level at Which to ConsiderDrug Therapy (mg/dL) CHD or CHD Risk Equivalents(10-year risk >20%) <100 100 130 (100–129: drug optional) 2+ Risk Factors (10-year risk 20%) <130 130 10-year risk 10–20%: 130 10-year risk <10%: 160 0–1 Risk Factor <160 160 190 (160–189: LDL-lowering drug optional) LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)and Drug Therapy in Different Risk Categories

  13. Major Risk Factors that Modify LDL-Goals • Cigarette smoking • hypertension (BP>140/90 or on anti-hypertensive medication) • low HDL-C (<40mg/dl) • high HDL-C (>60mg/dl) “negative risk factor” • family history of premature CHD • 1o male relative < 55yrs • 1o female relative <65yrs • age • men > 45 yrs • women > 55 yrs

  14. Estimating 10-Year CHD RiskFramingham Risk Score • Short Term Risk (10-yr) for myocardial infarction • Based on: • Age • Total Cholesterol • Smoking status • HDL • Systolic BP

  15. Spreadsheet for determining Framingham 10-yr risk. • Downloadable at: • http://hin.nhlbi.nih.gov/atpiii/riskcalc.htm • Palm III Operating System download at: • http://hin.nhlbi.nih.gov/atpiii/atp3palm.htm • includes other information from ATP III

  16. Categories of Risk and LDL-C Goals

  17. Risk Category LDL Goal(mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (TLC) (mg/dL) LDL Level at Which to ConsiderDrug Therapy (mg/dL) CHD or CHD Risk Equivalents(10-year risk >20%) <100 100 130 (100–129: drug optional) 2+ Risk Factors (10-year risk 20%) <130 130 10-year risk 10–20%: 130 10-year risk <10%: 160 0–1 Risk Factor <160 160 190 (160–189: LDL-lowering drug optional) LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC)and Drug Therapy in Different Risk Categories

  18. Therapeutic Lifestyle Changes in LDL-lowering Therapy • TLC Diet • Therapeutic options to lower LDL-C • plant stanols/sterols (2g/d) • viscous soluble fiber (10-25 g/d) • Weight reduction • Increase physical activity

  19. TLC diet • SFA: < 7% of Calories • PUFA: up to 10% of Calories • MUFA: up to 20% of Calories • Total Fat: 25-35% of Calories • CHO: 50-60% of Calories • fiber: 20-30g/d • Cholesterol: < 200mg/d

  20. Visit 3 Visit 2 Evaluate LDLresponse If LDL goal notachieved, consideradding drug Tx Evaluate LDLresponse If LDL goal notachieved, intensifyLDL-Lowering Tx Visit I Begin LifestyleTherapies A Model of Steps in Therapeutic Lifestyle Changes (TLC) Visit N 6 wks 6 wks Q 4-6 mo MonitorAdherenceto TLC • Emphasizereduction insaturated fat &cholesterol • Encouragemoderate physicalactivity • Consider referral toa dietitian • Reinforce reductionin saturated fat andcholesterol • Consider addingplant stanols/sterols • Increase fiber intake • Consider referral toa dietitian • Initiate Tx forMetabolicSyndrome • Intensify weightmanagement &physical activity • Consider referral to a dietitian

  21. Beyond LDL Lowering:Metabolic Syndrome as a Secondary Target of Therapy • Cluster of risk factors • Associated with insulin resistance • Enhance risk of CHD at any LDL-C level

  22. Diagnosis of Metabolic Syndrome • Three or more of the following: • Abdominal Obesity • men > 40” waist circumference • women > 35” waist circumference • Hypertriglyceridemia (>150 mg/dl) • Low HDL • men < 40 mg/dl • women < 50 mg/dl • Hypertension (>130/>85 mmHg) • Hyperglycemia (> 110 mg/dl)

  23. Prevalence of the Metabolic Syndrome Among US AdultsJAMA 287:356-359 (2002) • NHANES III (8814 adults) • Prevalence • 23.7% of adult population • 47 million Americans • increases with age • 6.7% of 20-29 yr olds • 43.5% of 60-69 yr olds • overall, prevalence similar in men and women • African-American women 57% higher • Mexican-American women 26% higher

  24. Management of Metabolic Syndrome • Control LDL-cholesterol • Weight Control • enhances LDL-C lowering • reduces all risk factors of metabolic syndrome • Physical Activity • reduces VLDL-TG • increases HDL-C • lowers LDL-C • lowers BP • reduces insulin resistance

  25. ATP III Guidelines - Application • Step 1 • Determine lipoprotein levels from fasted blood sample • LDL-cholesterol • primary target of therapy • Total cholesterol • HDL-cholesterol

  26. ATP III Guidelines - Application • Step 2 • Identify presence of clinical atherosclerotic disease that confer high risk • Clinical CHD • CHD risk equivalents

  27. ATP III Guidelines - Application • Step 3 • Determine presence of major risk factors (other than LDL) • cigarette smoking • hypertension or anti HPT meds • low HDL • family history • age

  28. ATP III Guidelines - Application • Step 4 • If 2+ risk factors (other than LDL) without CHD or CHD equivalent, assess 10-year CHD risk • Framingham tables • > 20% = CHD risk equivalent

  29. ATP III Guidelines - Application • Step 5 • Determine risk category • CHD or CHD Risk Equivalent • 2+ Risk Factors • 1-1 Risk Factors • Establish LDL goal • Determine need for TLC based on LDL • Determine level for drug consideration

  30. ATP III Guidelines - Application • Step 6 • Initiate TLC if LDL is above goal • TLC diet • Weight management • Increase physical activity

  31. ATP III Guidelines - Application • Step 7 • consider adding drug therapy if LDL exceeds recommended levels • Drugs + TLC simultaneously if CHD or CHD equivalent • Add drugs to TLC after 3 months for other risk categories

  32. ATP III Guidelines - Application • Step 8 • Identify metabolic syndrome and treat, if present after 3 months of TLC • Clinical identification • abdominal obesity • hypertriglyceridemia • low HDL • hypertension • hyperglycemia

  33. ATP III Guidelines - Application • Step 8 (cont.) • Treat underlying causes • weight management • physical activity • Treat risk factors if they persist despite TLC • treat hypertension • use asprin • treat hypertriglyceridemia, low HDL

  34. ATP III Guidelines - Application • Step 9 • Treat elevated triglycerides • primary aim is to reach LDL goals • intensify weight management • increase physical activity • consider TG lowering drugs • if TG > 500mg/dl, 1st lower TG to prevent pancreatitis (VLFD)

  35. ATP III Guidelines - Application • Step 9 (cont.) • Treatment of low HDL • first reach LDL goal • intensify weight management and increase physical activity • consider drug treatment if TG normal

  36. Thanks!The End!

  37. Estimate of 10-Year Risk for Women (Framingham Point Scores)

  38. Estimate of 10-Year Risk for Women (Framingham Point Scores)

  39. Estimate of 10-Year Risk for Women (Framingham Point Scores)

  40. Estimate of 10-Year Risk for Women (Framingham Point Scores)

  41. Estimate of 10-Year Risk for Women (Framingham Point Scores)

  42. Estimate of 10-Year Risk for Women (Framingham Point Scores)

  43. Estimate of 10-Year Risk for Women (Framingham Point Scores)

  44. Who, me worry ???

More Related